PMID- 30345333
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220322
IS  - 2332-7812 (Print)
IS  - 2332-7812 (Electronic)
IS  - 2332-7812 (Linking)
VI  - 5
IP  - 6
DP  - 2018 Nov
TI  - Gender differences in prednisone adverse effects: Survey result from the MG 
      registry.
PG  - e507
LID - 10.1212/NXI.0000000000000507 [doi]
LID - e507
AB  - OBJECTIVE: Prednisone is a first-line immunosuppressive treatment for myasthenia 
      gravis (MG), whereas short-term and long-term adverse effects (AEs) are a 
      limiting factor in its usage. METHOD: The MG patient registry is a 
      patient-driven, nation-wide database with patients of age >/=18 years, who were 
      diagnosed with MG and live in the United States. Custom-designed 
      "prednisone-steroid use and MG" survey was sent out to MG registry participants 
      as part of semi-annual follow-up. Data were collected and analyzed for frequency. 
      RESULTS: A total of 398 MG participants (21% response rate) completed the survey, 
      including 173 men and 225 women. Among them, 298 reported current (174) or past 
      (288) prednisone intake. Current prednisone dosage varied from 0.5 to 75 mg 
      (median 10 mg, IQR 7-20), dosing frequency was daily in 132 (76%) and every other 
      day in 31 (18%). Peak prednisone dose was commonly between 25 mg and 60 mg 
      (Median 50 mg, IQR 25-60); however, doses more than 60 mg daily were reported in 
      59 (20%). Prednisone AEs were reported more commonly in women (95% vs 81%, p < 
      0.0001). Women reported more intolerable AEs (77% vs 50%, p < 0.00001) and less 
      willingness to accept a dose increase (26% vs 44%, p = 0.03) compared with men. 
      CONCLUSIONS: Prednisone is commonly used in the treatment of MG, with highly 
      variable dosages and dosing frequencies reflecting the absence of a standard 
      guideline. Intolerable AEs were more commonly reported among women and was 
      associated with unwillingness to accept a dose increase. Consensus guidelines and 
      their validation are required to guide prednisone treatment for MG.
FAU - Lee, Ikjae
AU  - Lee I
AD  - Department of Neurology (I.L.), University of Alabama, Birmingham; Department of 
      Neurology (H.J.K.), the George Washington University; and Department of 
      Biostatistics (T.M., M.F., G.C.), University of Alabama, Birmingham.
FAU - Kaminski, Henry J
AU  - Kaminski HJ
AD  - Department of Neurology (I.L.), University of Alabama, Birmingham; Department of 
      Neurology (H.J.K.), the George Washington University; and Department of 
      Biostatistics (T.M., M.F., G.C.), University of Alabama, Birmingham.
FAU - McPherson, Tarrant
AU  - McPherson T
AD  - Department of Neurology (I.L.), University of Alabama, Birmingham; Department of 
      Neurology (H.J.K.), the George Washington University; and Department of 
      Biostatistics (T.M., M.F., G.C.), University of Alabama, Birmingham.
FAU - Feese, Michelle
AU  - Feese M
AD  - Department of Neurology (I.L.), University of Alabama, Birmingham; Department of 
      Neurology (H.J.K.), the George Washington University; and Department of 
      Biostatistics (T.M., M.F., G.C.), University of Alabama, Birmingham.
FAU - Cutter, Gary
AU  - Cutter G
AD  - Department of Neurology (I.L.), University of Alabama, Birmingham; Department of 
      Neurology (H.J.K.), the George Washington University; and Department of 
      Biostatistics (T.M., M.F., G.C.), University of Alabama, Birmingham.
LA  - eng
PT  - Journal Article
DEP - 20181015
PL  - United States
TA  - Neurol Neuroimmunol Neuroinflamm
JT  - Neurology(R) neuroimmunology & neuroinflammation
JID - 101636388
PMC - PMC6192695
EDAT- 2018/10/23 06:00
MHDA- 2018/10/23 06:01
PMCR- 2018/10/15
CRDT- 2018/10/23 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2018/08/07 00:00 [accepted]
PHST- 2018/10/23 06:00 [entrez]
PHST- 2018/10/23 06:00 [pubmed]
PHST- 2018/10/23 06:01 [medline]
PHST- 2018/10/15 00:00 [pmc-release]
AID - NEURIMMINFL2018017814 [pii]
AID - 10.1212/NXI.0000000000000507 [doi]
PST - epublish
SO  - Neurol Neuroimmunol Neuroinflamm. 2018 Oct 15;5(6):e507. doi: 
      10.1212/NXI.0000000000000507. eCollection 2018 Nov.